No connection

Search Results

RGEN

BEARISH
$118.29 Live
Repligen Corporation · NASDAQ
Target $179.78 (+52.0%)
$109.5 52W Range $175.77
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 28, 2026
Market cap
$6.67B
P/E
137.55
ROE
2.4%
Profit margin
6.6%
Debt/Equity
0.33
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
RGEN exhibits a critical disconnect between its market valuation and fundamental performance, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a current price ($118.29) that vastly exceeds its Graham Number ($26.9) and Intrinsic Value ($6.02). While the balance sheet is exceptionally liquid with a Current Ratio of 8.37 and low debt, the company is suffering from a severe earnings collapse (-47.7% YoY EPS growth) and a negligible ROE of 2.40%. Despite bullish analyst targets, the combination of a PEG ratio of 8.23, bearish insider selling, and a negative 5-year price trend suggests the stock is significantly overvalued.

Key Strengths

Exceptional short-term liquidity (Current Ratio: 8.37)
Conservative leverage profile (Debt/Equity: 0.33)
Consistent double-digit revenue growth (18.10% YoY)
Strong gross profit margins (52.65%)
Strong analyst backing with a high mean target price ($179.78)

Key Risks

Extreme valuation premium (P/E: 137.55, PEG: 8.23)
Severe deterioration in earnings growth (-47.7% YoY EPS)
Very poor capital efficiency (ROE: 2.40%)
Bearish insider sentiment with $9.12M in recent sales
Persistent long-term price decline (-46.2% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$28.5
-75.9% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
30
Weak
Value
10
Future
45
Past
20
Health
75
Dividend
0
AI Verdict
Overvalued Growth Trap
Key drivers: Extreme P/E vs ROE disparity, Negative EPS growth, Strong balance sheet liquidity
Confidence
90%
Value
10/100

Ref P/E, PEG, Graham Number

Positives
No standout positives identified.
Watchpoints
  • P/E of 137.55 is unsustainable
  • PEG ratio of 8.23 indicates massive overpayment for growth
  • Price is >4x the Graham Number
Future
45/100

Ref Growth rates

Positives
  • Revenue growth remains steady at 18%
Watchpoints
  • Earnings growth is crashing (-47.7% YoY)
  • Forward P/E remains high at 46.99
Past
20/100

Ref Historical trends

Positives
  • Historical ability to beat earnings estimates in earlier years
Watchpoints
  • 5-year return of -46.2%
  • Recent 6-month decline of -26.6%
Health
75/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Very low Debt/Equity (0.33)
  • Massive liquidity cushion (Current Ratio 8.37)
Watchpoints
  • Piotroski F-Score of 4/9 is only 'Stable', not 'Strong'
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$118.29
Analyst Target
$179.78
Upside/Downside
+52.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RGEN and closest competitors.

Updated 2026-04-27
RGE
Repligen Corporation
Primary
5Y
-46.2%
3Y
-22.0%
1Y
-17.6%
6M
-26.6%
1M
+7.4%
1W
-10.4%
HQY
HealthEquity, Inc.
Peer
5Y
+11.9%
3Y
+34.2%
1Y
-2.5%
6M
-13.9%
1M
-0.8%
1W
-7.9%
ACL
Arcellx, Inc.
Peer
5Y
+580.9%
3Y
+279.9%
1Y
+59.8%
6M
+50.1%
1M
+63.7%
1W
+0.1%
HIM
Hims & Hers Health, Inc.
Peer
5Y
+138.0%
3Y
+153.6%
1Y
+3.2%
6M
-39.1%
1M
+51.6%
1W
-5.2%
GRF
Grifols, S.A.
Peer
5Y
-51.1%
3Y
+11.6%
1Y
+28.0%
6M
-11.9%
1M
+2.2%
1W
-0.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
137.55
Forward P/E
46.99
PEG Ratio
8.23
P/B Ratio
3.16
P/S Ratio
9.04
EV/Revenue
8.92
EV/EBITDA
52.92
Market Cap
$6.67B

Profitability

Profit margins and return metrics

Profit Margin 6.62%
Operating Margin 8.26%
Gross Margin 52.65%
ROE 2.4%
ROA 0.99%

Growth

Revenue and earnings growth rates

Revenue Growth +18.1%
Earnings Growth N/A
Q/Q Revenue Growth +18.12%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.33
Low debt
Current Ratio
8.37
Strong
Quick Ratio
6.82
Excellent
Cash/Share
$13.63

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.2B
Gross Margin
52.5%
Op. Margin
8.3%
Net Margin
6.7%
Total Assets
$2.9B
Liabilities
$0.8B
Equity
$2.1B
Debt/Equity
0.40x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
68%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-02-24
$0.23
+3.5% surprise
2025-10-28
$0.46
+10.9% surprise
2025-07-29
$0.37
-5.0% surprise

Healthcare Sector Comparison

Comparing RGEN against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
P/E Ratio
137.55
This Stock
vs
75.44
Sector Avg
+82.3% (Expensive)
Return on Equity (ROE)
2.4%
This Stock
vs
-88.14%
Sector Avg
-102.7% (Below Avg)
Profit Margin
6.62%
This Stock
vs
-16.28%
Sector Avg
-140.7% (Weaker)
Debt to Equity
0.33
This Stock
vs
2.66
Sector Avg
-87.7% (Less Debt)
Revenue Growth
18.1%
This Stock
vs
124.04%
Sector Avg
-85.4% (Slower)
Current Ratio
8.37
This Stock
vs
4.47
Sector Avg
+87.2% (Stronger)

Similar Companies

Peer comparison within the same industry

RGEN Repligen Corporation
BEARISH
Mkt Cap
$6.7B
P/E
137.5
ROE
2.4%
Price
$118.29
HQY HealthEquity, Inc.
NEUTRAL
Mkt Cap
$6.7B
P/E
31.7
ROE
10.2%
Price
$77.96
 Compare with RGEN
ACLX Arcellx, Inc.
BEARISH
Mkt Cap
$6.7B
P/E
-
ROE
-53.4%
Price
$114.39
 Compare with RGEN
HIMS Hims & Hers...
NEUTRAL
Mkt Cap
$6.7B
P/E
57.6
ROE
25.2%
Price
$29.39
 Compare with RGEN
GRFS Grifols, S.A.
NEUTRAL
Mkt Cap
$6.7B
P/E
12.8
ROE
6.2%
Price
$8.21
 Compare with RGEN

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

LOEILLOT OLIVIER
Chief Executive Officer
Sell
2026-04-21
3,832 shares · $536,480
KURIYEL RALF
Officer
Stock Award
2026-03-05
5,284 shares
GARLAND JASON K.
Chief Financial Officer
Stock Award
2026-03-05
7,751 shares
BYLUND JAMES
Chief Operating Officer
Stock Award
2026-03-05
7,751 shares
LOEILLOT OLIVIER
Chief Executive Officer
Stock Award
2026-03-05
24,134 shares
KURIYEL RALF
Officer
Stock Award
2026-03-04
125 shares
BYLUND JAMES
Chief Operating Officer
Stock Award
2026-03-04
125 shares
DOUGLASS BRIAN ROBB
Officer
Stock Award
2025-12-31
2,288 shares
DAWES KAREN A
Director
Sell
2025-12-17
275 shares · $44,275
MUIR GLENN P
Director
Option Exercise
2025-12-16
3,366 shares · $87,920
LOEILLOT OLIVIER
Chief Executive Officer
Sell
2025-11-25
7,041 shares · $1,196,970
BYLUND JAMES
Chief Operating Officer
Sell
2025-11-18
2,191 shares · $331,301
HUNT ANTHONY JOHN
Director
Sell
2025-11-13
20,000 shares · $3,092,278
HUNT ANTHONY JOHN
Director
Option Exercise
2025-11-13
2,952 shares · $99,984
HUNT ANTHONY JOHN
Director
Sell
2025-11-12
25,000 shares · $3,921,940
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-02

RGEN filed a Definitive Proxy Statement (DEF 14A) on April 2, 2026, providing shareholders with necessary information and voting materials for the upcoming annual meeting.

10-K
10-K
2026-02-26

RGEN filed its annual 10-K on February 26, 2026. The provided excerpts do not contain specific financial metrics or detailed risk factors for analysis.

8-K
8-K
2026-02-24

Regeneron Pharmaceuticals, Inc. reported its fourth-quarter and full-year financial results.

8-K
8-K
2026-01-06

Regeneron Pharmaceuticals filed an 8-K on January 6, 2026, likely reporting a material corporate update or financial guidance for the new fiscal year.

10-Q
10-Q
2025-11-04

RGEN filed its 10-Q on November 4, 2025. The provided excerpts do not contain specific financial highlights or detailed risk factors beyond a reference to Item 1A.

8-K
8-K
2025-10-28

Regenxbio Inc. filed an 8-K on October 28, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-09-02
10-Q
10-Q
2025-08-07

RGEN filed its 10-Q on August 7, 2025. While the filing identifies risk factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available excerpts.

8-K
8-K
2025-07-29

Regeneron Pharmaceuticals, Inc. filed an 8-K likely announcing its second-quarter financial results for 2025.

8-K
8-K
2025-05-15
10-Q
10-Q
2025-04-29
8-K
8-K
2025-04-29
DEF 14A
DEF 14A
2025-04-04
10-K
10-K
2025-03-14
8-K
8-K
2025-02-20
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
18 analysts
Canaccord Genuity
2026-04-20
Maintains
Hold Hold
Roth Capital
2026-04-17
init
Buy
Barclays
2026-04-14
Maintains
Overweight Overweight
Evercore ISI Group
2026-04-06
Maintains
Outperform Outperform
HC Wainwright & Co.
2026-03-23
Maintains
Buy Buy
UBS
2026-02-25
Maintains
Buy Buy
Barclays
2026-02-25
Maintains
Overweight Overweight
Wells Fargo
2026-02-25
Maintains
Overweight Overweight
Evercore ISI Group
2026-02-25
Maintains
Outperform Outperform
UBS
2026-01-16
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning RGEN from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile